With Roche's top three oncology meds facing biosimilar challengers in the U.S., the days of peak sales for at least two look to be coming to a rapid end. One of those, Rituxan, was the last of the three to face copycat challengers—but the damage could be dramatic in the coming years.
Rituxan hit $6.54 billion in sales in 2019, putting it second behind colorectal cancer therapy Avastin in terms of sales for Roche's blockbuster oncology troika. With biosims already on the U.S. market, Evaluate Pharma predicts that Rituxan's sales could plummet to just $1.84 billion in 2026.
Like copycats for both Avastin and Herceptin, U.S. biosimilars came after Rituxan in the back half of 2019.